Table 2.
Overall survival in NEC cohort and invasive mammary carcinoma cohort according to clinical stage (2003–2009)
| Cohort | n | Median survival in months (IQR) | 5-year OS rate (95% CI) | P |
|---|---|---|---|---|
|
All |
|
|
|
<0.0001 |
| NEC |
135 |
26 (12–48) |
53.6 (42.2-63.7) |
|
| IMC |
374,598 |
34 (16–56) |
79.8 (79.6-79.9) |
|
|
Stage I |
|
|
|
0.002 |
| NEC |
32 |
33 (17–51) |
74.4 (43.4-90.0) |
|
| IMC |
170,778 |
36 (18–58) |
89.6 (89.2-89.6) |
|
|
Stage II |
|
|
|
<0.0001 |
| NEC |
49 |
30 (19–52) |
73.9 (56.3-85.3) |
|
| IMC |
123,430 |
36 (17–58) |
82.4 (82.1-82.7) |
|
|
Stage III |
|
|
|
0.014 |
| NEC |
16 |
19 (13–41) |
58.2 (21.0-82.8) |
|
| IMC |
41,422 |
29 (14–48) |
72.4 (71.8-73.1) |
|
|
Stage IV |
|
|
|
NS |
| NEC |
32 |
12 (4–25) |
20.7 (5.70-42.1) |
|
| IMC | 17,830 | 15 (5–30) | 27.9 (26.9-29.0) |
Data from the Surveillance, Epidemiology and End Results Program, 2003 to 2009. NEC, neuroendocrine carcinoma; IMC, invasive mammary carcinoma; IQR, interquartile range; OS, overall survival; n, number of cases; HR, hazard ratio; CI, confidence interval; NS, not significant.